GST : 33ACGPF5198L1ZB
Write a Review
Our Products
We offer the best product range of Lyophilized Vials Jubi and Paxista Tablets.
Jubi-R Injection is an antiviral drug that belongs to the category of purine nucleosides, containing the active ingredient Remdesivir. It is used in the treatment of coronavirus disease(COVID-19). It is an infectious respiratory disease caused by the severe acute respiratory syndrome named coronavirus 2 (SARS-CoV-2) virus.
This drug is contraindicated in individuals with known hypersensitivity (allergic) reactions to the medication or any of its components. If an individual has previously experienced a severe allergic reaction to this drug, they should not receive the medication. Also, this use is contraindicated in patients with severe hepatic impairment and can cause severe liver-related adverse effects. Close monitoring of liver function is recommended during treatment with this drug. If significant liver function abnormalities are observed, treatment should be discontinued.
It is highly advised to use this drug cautiously in individuals with renal impairment (moderate to severe kidney disease), as it is primarily eliminated from the body through the kidneys. Monitoring renal function and adjusting the dose accordingly in patients with pre-existing renal impairment is necessary. It is unknown whether Jubi-R injection will affect the unborn baby. Inform your physician beforehand if you are pregnant or think you might be pregnant. Talk to your doctor if you take any other medications or before using over-the-counter or herbal products. Your doctor will evaluate the risk of interaction with this medication.
Additional Information:
Payment Terms : T/T, Western Union
Paxlovid is an investigational medicine used to treat mild-to-moderate COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
PAXLOVID is investigational because it is still being studied. There is limited information about the safety and effectiveness of using PAXLOVID to treat people with mild-to-moderate COVID-19.
The FDA has authorized the emergency use of PAXLOVID for the treatment of mild-to-moderate COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with a positive test for the virus that causes COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, under an EUA.
If you test positive for COVID19, talk to your healthcare provider as soon as possible. Your healthcare provider can tell you about your treatment options and if PAXLOVID is appropriate for you.
People of all ages or groups can be infected with COVID-19. Some people are more likely than others to get very sick from COVID-19, which can lead to hospitalization or death, even when symptoms start off as mild.
Some people are at a greater risk of COVID-19 becoming severe because they meet certain criteria, including where they live, work, or have difficulty accessing health care. This includes many people from racial and ethnic minority groups and people with disabilities.
In addition, having one or more of the following factors puts you at high risk of getting severe COVID-19*:
Additional Information:
Payment Terms : T/T, Western Union
Mr. Abdul Muthaliff (Taj Distributors)
43, Lambert Nagar, 3rd Cross Street, Virugambakkam, Chennai, Tamil Nadu - 600092, India
https://www.tajdistributors.co.in
Share us via
